Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
INB-400 by IN8bio for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
INB-400 is under clinical development by IN8bio and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData,...
INB-410 by IN8bio for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
INB-410 is under clinical development by IN8bio and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of IN8bio's INB-100?
INB-100 is a gene-modified cell therapy commercialized by IN8bio, with a leading Phase I program in Acute Lymphocytic Leukemia (ALL,...
Risk adjusted net present value: What is the current valuation of IN8bio's INB-400?
INB-400 is a gene-modified cell therapy commercialized by IN8bio, with a leading Phase II program in Recurrent Glioblastoma Multiforme (GBM)....